The present invention relates to the development of matrix type transdermal patch of diltiazem hydrochloride using solid lipid nanoparticles to reduce dose size, side effects, adverse effects and toxicity in conventional therapy of arrhythmia. Diltiazem hydrochloride is a BCS class III drug (high solubility and low permeability) with hydrophilic nature having poor bioavailability and undergoes first pass metabolism. The problem of low permeability can be solve by preparing solid lipid nanoparticles and used as a carrier in development of transdermal patch with an objective to improve permeation via skin which in turn will improve patient compliance.
